The endocrine therapy drugs (ETDs) market comprises drugs such as aromatase inhibitors, antiestrogens, and gonadotropin-releasing hormone agonists used for the treatment of hormone receptor-positive cancers such as breast cancer and prostate cancer. ETDs work by blocking the effects of hormones like estrogen and progesterone that promote the growth of cancer cells in hormone receptor-positive cancers.
The Global Endocrine Therapy Drugs (ETDs) Market is estimated to be valued at US$ 35060.96 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in the endocrine therapy drugs (ETDs) market are Johnson & Johnson (US), Procter & Gamble (US), Kimberly-Clark (US), Essity Aktiebolag (publ) (Sweden), Kao Corporation (Japan), Daio Paper Corporation (Japan), Unicharm Corporation (Japan), Premier FMCG (South Africa), Ontex (Belgium), Hengan International Group Company Ltd. (China), Drylock Technologies (Belgium), Natracare LLC (US), First Quality Enterprises, Inc. (US), Bingbing Paper Co., Ltd. (China). The increasing prevalence of hormone receptor-positive cancers and rising awareness about the efficacy of ETDs in treating breast and prostate cancers are fueling demand in the global market. Moreover, major players are focusing on expanding their operations in developing regions to tap the growth opportunities offered.
Market key trends
One of the key trends gaining prominence in the Global Endocrine Therapy Drugs (Etds) Market Size is the development of novel selective estrogen receptor degraders (SERDs). SERDs act by degrading the estrogen receptor and blocking estrogen signaling more effectively than aromatase inhibitors and selective estrogen receptor modulators (SERMs). This makes SERDs a more potent class of drugs for the treatment of advanced estrogen receptor-positive breast cancer. Several pharmaceutical companies are conducting phase III clinical trials to evaluate the safety and efficacy SERDs for various cancer indications. This is expected to significantly boost the ETDs market during the forecast period.
Porter's Analysis
Threat of new entrants:The presence of established players in the ETDs market poses a high entry barrier for new players due to capital requirements and compliance with regulations.
Bargaining power of buyers: The bargaining power of buyers is moderate as ETDs are indispensable for cancer treatment. However, the availability of generic alternatives provides some bargaining power to buyers.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of multiple raw material suppliers in the market. Suppliers cannot influence prices due to the availability of substitute materials.
Threat of new substitutes: The threat of substitutes is low as there are limited treatment alternatives for cancer currently. However, the development of personalized medicine may increase the availability of substitutes.
Competitive rivalry: The ETDs market witnesses high competition due to the presence of numerous international and regional players. Price wars among existing competitors further intensify the rivalry.
Geographical Regions
North America dominates the global ETDs market and accounted for around 40% of the total market share in 2024, followed by Europe. High healthcare expenditure, growing geriatric population, and rising cancer incidence in the US and Canada fuel the regional market growth.
The Asia Pacific region is expected to be the fastest-growing market during the forecast period. Improving access to healthcare facilities, increasing healthcare expenditure, growing awareness about cancer treatment, and rising affordability are key factors driving the APAC ETDs market. Rising cancer incidences in countries such as China and India will further propel the regional demand.
For more Insights, Read –
https://www.newswirestats.com/endocrine-therapy-drugs-etds-market-market-size-and-share-analysis/
